Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone

Encephale

Volumn 34, Issue 2, 2008, Pages 170-178

  Llorca, P M ^a   Bouhours, P ^b   Moreau Mallet, V ^b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b Janssen Cilag   (France)

Author keywords

Functioning; Long acting risperidone; Quality of life; Tolerability

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; FLUPENTIXOL DECANOATE; FLUPHENAZINE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PIPOTIAZINE PALMITATE; PSYCHOTROPIC AGENT; RISPERIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMPOTENCE; INJECTION SITE REACTION; INSOMNIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OPEN STUDY; PATIENT SATISFACTION; POSITIVE SYNDROME; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CATCHMENT AREA (HEALTH); DELAYED-ACTION PREPARATIONS; DEPRESSION, POSTPARTUM; FEMALE; FRANCE; HUMANS; INJECTIONS, INTRAMUSCULAR; PATIENT SATISFACTION; PREGNANCY; PREGNANCY OUTCOME; QUESTIONNAIRES; RISPERIDONE; SEVERITY OF ILLNESS INDEX;

EID: 43049090149     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2007.06.004     Document Type: Article

References (41)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
3. Andreasen N.C., Carpenter Jr. W.T., Kane J.M., et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162 (2005) 441-449
4. Awad A.G., and Voruganti L.N.P. New antipsychotics, compliance, quality of life and subjective tolerability - are patients better off?. Can J Psychiatry 49 (2004) 297-302
5. Barnes T.R., and Curson D.A. Long-term depot antipsychotics: a risk-benefit assessment. Drug Saf 10 (1994) 464-479
6. Bengtsson-Tops A., and Hansson L. Subjective quality of life in schizophrenic patients living in the community. Relationship to clinical and social characteristics. Eur Psychiatry 1999 (1999) 256-263
7. Bhanji N.H., Chouinard G., and Margolese H.C. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 14 (2004) 87-92
8. Bonora E., Kiechl S., Willeit J., et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the bruneck study. Diabetes 53 (2004) 1782-1789
9. Casey D.E., Haupt D.W., Newcomer J.W., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 (2004) 4-18
10. Chouinard G., Ross-Chouinard A., Annable L., et al. Extrapyramidal symptom rating scale. Can J Neurol Sci 7 (1980) 233
11. Chue P. Risperidone long-acting injection. Expert Rev Neurotherapeutics 3 (2003) 435-446
12. Chue P., and Cheung R. The impact of weight gain associated with atypical antipsychotic use in schizophrenia. Acta Neuropsychiatr 16 (2004) 1-11
13. Csernansky JG., Mahmoud R., Brenner R., and R-U-S Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346 (2002) 16-L22
14. Csernansky J.G., and Schuchart E.K. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16 (2002) 473-484
15. Dolder C.R., Lacro J.P., Dunn L.B., et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am J Psychiatry 159 (2002) 103-108
16. Eerdekens M, Fleischhacker WW, Xie Y et al. (2002). Long-term safety of long-acting risperidone microspheres. The American Psychiatric Nurses Association annual meeting, 5-8 October, Dallas, Texas. American Psychiatric Nurses Association.
17. Ereshefsky L., and Mascarenas C.A. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 64 (2003) 18-23
18. Fleischhacker W.W., Eerdekens M., Karcher K., et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry 64 (2003) 1250-1257
19. Gilmer T.P., Dolder C.R., Lacro J.P., et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161 (2004) 692-699
20. Guy W. Clinical global impressions. In: ECDEU assessment manual for psychopharmacology 76 (1976), Department of Health, Education and Welfare, Rockville: Md 218-220
21. Harrison T.H., and Goa K.L. Long-acting risperidone. A review of its use in schizophrenia. CNS Drugs 18 (2004) 113-132
22. Kane J. Progress defined - short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol 16 (2001) S1-S8
23. Kane J.M., Aguglia E., Altamura A.C., et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8 (1998) 55-66
24. Kane J.M., Eerdekens M., Lindenmayer J.P., et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160 (2003) 1125-1132
25. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
26. Keith S.J., and Kane J.M. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64 (2003) 1308-1315
27. Lambert M., and Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 18 (2004) 5-17
28. Lasser R.A., Bossie C.A., Gharabawi G., et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 19 (2004) 219-225
29. Leucht S., Barnes T.R., Kissling W., et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160 (2003) 1209-1222
30. Lindenmayer J.P., Eerdekens E., Berry S.A., et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-Week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65 (2004) 1084-1089
31. Mahmoud R.A., Engelhart L.M., Janagap C.C., et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder. Symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004 (2004) 275-286
32. Marder S.R. Overview of partial compliance. J Clin Psychiatry 64 (2003) 3-9
33. Marder S.R., Davis J.M., and Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58 (1997) 538-546
34. ®): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31 (1993) 247-263
35. Moeller H., Llorca P., Sacchetti E., et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20 (2005) 121-130
36. Nasrallah H.A., Duchesne I., Mehnert A., et al. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 65 (2004) 531-536
37. Pereira S., and Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 95 (1997) 464-468
38. Tunis S.L., Croghan T.W., Heilman D.K., et al. Reliability, validity and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 37 (1999) 678-691
39. Turner M., Eerdekens E., Jacko M., et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 19 (2004) 241-249
40. van Os J., Bossie C.A., and Lasser R.A. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 19 (2004) 229-232
41. ®): I. Conceptual framework and item selection. Med Care 30 (1992) 473-483